20 (AIDX) EBITDA (2025 - 2026)

20 (AIDX) posted EBITDA of -$1.4 million for Q1 2026, down 86.92% on a QoQ basis from -$772180.0 in Q1 2025, and down 86.92% year-over-year from -$11.0 million in Q1 2025.

20 (AIDX) EBITDA (2025 - 2026) Analysis & Trends

20's EBITDA history runs 2 years deep, the most recent figure standing at -$1.4 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Abbott Laboratories 182.52 Bn 175.22 Bn 6.27 Bn 1.35 Bn
2 Stryker 128.96 Bn 126.09 Bn 3.81 Bn 936.00 Mn
3 Medtronic 107.99 Bn 98.77 Bn 6.41 Bn 1.87 Bn
4 Boston Scientific 67.76 Bn 66.31 Bn 3.61 Bn 1.10 Bn
5 Edwards Lifesciences 48.09 Bn 44.41 Bn 1.29 Bn 477.60 Mn
6 Dexcom 28.30 Bn 27.18 Bn 750.30 Mn 255.30 Mn
7 GE HealthCare Technologies 27.89 Bn 25.61 Bn 1.98 Bn 515.00 Mn
8 Smith & Nephew 27.02 Bn 26.45 Bn - -
9 Koninklijke Philips 23.98 Bn 20.86 Bn 2.07 Bn 282.15 Mn
10 20 3.47 Mn -747,311.48 62,884.00 -1.44 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.44 Mn
Mar 31, 2025 -772,180.00